Theravance Biopharma, Inc. is a business that focuses on manufacturing biopharmaceuticals as its primary line of business (NASDAQ: TBPH). In a research note made public on Monday, September 19th, SVB Leerink lowered its projections for the earnings per share expected to be generated by Theravance Biopharma during the third quarter of 2022. According to projections by G. Porges, an analyst working for SVB Leerink, the biopharmaceutical industry will earn $0.27 per share in the fourth quarter. This figure represents a decline from the prior projection, which was $0.24 per share. Theravance Biopharma’s complete fiscal year is not yet over, but analysts anticipate a profit of $0.85 per share for the company. SVB Leerink anticipated a profit of $0.27 for the business operations of Theravance Biopharma during the fourth quarter of 2022. During the financial year 2022, the company posted a loss of $0.99 in earnings per share. The earnings per share for the first quarter of 2023 came in at $0.42, while the earnings per share for the second quarter of 2023 came in at $0.21.
The earnings per share for the company during the third quarter of 2023 amounted to $0.27. The annual profits for the fiscal years 2023 and 2024 were $0.93, $0.49, and $0.40, respectively. The earnings per share for the fourth quarter of the fiscal year 2023 were $0.17. In the second piece of research released on Thursday, July 14th, HC Wainwright reiterated their “buy” recommendation on shares of Theravance Biopharma and set their target price at $12.00. This price was originally set when the “buy” recommendation was initially issued. The stock has had a total of four different recommendations from investment analysts: two recommendations to hold, two recommendations to buy, and one suggestion to sell. According to Bloomberg.com, the firm is currently classified as having a consensus rating of “Hold,” and the average price goal for the company is currently set at $11.75. At the opening of trade on Thursday, the price of a share of Theravance Biopharma was $10.09 per share. The company’s simple moving average over fifty days is $9.27, and the simple moving average over two hundred days is $9.33. During the previous year, the price of Theravance Biopharma’s products fluctuated between $6.97 and $13.17 at various points. The price as of right now is $13.17.
The most recent financial results for Theravance Biopharma (NASDAQ: TBPH), released to the public on August 4th, can be found here. The biopharmaceutical company reported earnings of $0.04 per share for the quarter, which was $0.02 more than the average forecast of $0.06 by industry analysts. However, the revenue for the quarter came in at $11.05 million, which is much lower than the average expectation of $17.47 million, which was the forecast for the period. In addition, the corporation reported a loss of $0.80 per share for the same quarter it had reported the previous year.
Several institutional investors have recently modified how they are invested in the company to take advantage of new opportunities. Theravance Biopharma was one of the companies in which Vanguard Group Inc.’s holdings had a 10.3% gain in the first three months of the year. The stock of the biopharmaceutical firm is now owned by Vanguard Group Inc. in the amount of 6,947,947 shares, following the acquisition of an additional 648,124 shares during the most recent quarter. Their holdings are currently worth $66,421,000 in the market as of right now.
During the second quarter, Park West Asset Management LLC achieved an 833.23% gain in the proportion of Theravance Biopharma stock it owned. After purchasing an additional 2,833,254 shares during the most recent quarter, Park West Asset Management LLC now owns a total of 3,173,254 shares of the biopharmaceutical company’s stock, which has a value of $28,750,000. This brings the total number of shares owned by Park West Asset Management LLC to 3,173,254. During the second quarter, Woodline Partners LP achieved a 69.1% gain in the proportion of Theravance Biopharma shares it possessed. After purchasing an additional 916,820 shares of the biopharmaceutical company during the most recent fiscal quarter, Woodline Partners LP now has a total of 2,243,473 shares. The current price of these shares puts their market value at $20,326,000. Theravance Biopharma was added to State Street Corporation’s assets in an amount that was 13.3% higher than after the first three months of 2018. State Street Corp currently possesses a total of 1,541,533 of the company’s shares, which gives it a market value of $14,730,000.
This was made possible due to purchasing an additional 181,331 shares over the preceding quarter. And last, during the first quarter of this year, Goldman Sachs Group Inc. boosted the amount of Theravance Biopharma stock that is owned by 184.0%, bringing its total ownership percentage to 100%. After making additional purchases totaling 632,582 shares during the most recent fiscal quarter, Goldman Sachs Group Inc. now has 976,373 shares of the biopharmaceutical company’s stock in its possession. The price per share of the stock is at present $9,335,000.
In addition, Senior Vice President of Theravance Biopharma Richard A. Graham sold 15,086 shares of the company’s stock on Tuesday, August 9th. A total of 132,605.94 dollars’ worth of stock was traded at an average price of $8.79 per share, making the total value of the transaction $132,605.94. The senior vice president now directly controls 369,651 shares of the company as a direct result of the transaction that took place earlier. These shares have a value of about $3,249,232.29 each based on the underlying stock’s current price. You will be taken to a document submitted to the SEC if you click on the link we have provided for you, where you will find additional information regarding the sale.
On Tuesday, August 9th, Senior Vice President of Theravance Biopharma Richard A. Graham sold 15,086 shares of the company’s stock. This is one of the latest happenings in connection with this topic. A total of 132,605.94 dollars’ worth of stock was traded at an average price of $8.79 per share, making the total value of the transaction $132,605.94.
The senior vice president now directly owns 369,651 shares of the company’s stock as a direct result of the transaction. The senior vice president has a value of approximately $3,249,232.29 based on the current price of the company’s stock. On the Securities and Exchange Commission website, you may find a copy of the legal document that provides a more in-depth description of the sale.
The document in question outlines the sale of the asset. In addition to that, on August 16th, Senior Vice President Richard A. Graham sold 4,906 shares of Theravance Biopharma stock. A total of 47,637.26 dollars’ worth of the company’s stock was traded for $9.71 per share, making the total value of the transaction 47,637.26 dollars. As a direct consequence of the transaction, the senior vice president now holds direct ownership of 364,745 shares. The current market value of these shares is $3,541,673.95. The disclosure about the purchase can be seen in this particular location. There are a total of 4.8 percent of the company’s shares that corporate insiders hold.